UNSPSC 51431510: Arginine hydrochloride

This classification denotes a nutritional supplement, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier F7LTH1E20Y. European Medicines Agency schedules Arginine hcl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00579MIG. Arginine hydrochloride generally arises in the molecular formula C6H14N4O2.CLH. The term 'arginine hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.

UNSPSC 51431510 Arginine hydrochloride, a Commodity code, covers pharmaceutical raw materials and finished medications supplied to state and local healthcare, emergency response, and public health systems. State and local governments procure under this code primarily through emergency medical service providers, healthcare departments, and cooperative purchasing alliances that source branded and generic medications for clinical use, with recent activity showing demand for advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include municipal fire and rescue departments, state health and human services commissions, and regional cooperative purchasing organizations serving multiple state and local members. The Tampa Fire Rescue procurement and the Minnesota MMCAP alliance represent the two main issuing-body patterns: direct municipal purchasing for immediate operational needs and multi-state cooperative vehicles that aggregate demand across participating jurisdictions to achieve volume pricing and standardized supply-chain relationships with authorized wholesalers.

Recent activity concentrates in Florida, Minnesota, and Texas. The City of Tampa issued an IFB (Bid No. 26P00188) due April 8, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem totaling an estimated $40,000.00, with a 5 percent small local business enterprise bid discount available. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota, Oregon, and other member states, with contract effectiveness July 1, 2026, and a two-year initial term. The Texas Health and Human Services Commission issued an RFI posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intent to shift from traditional pharmacy benefit manager intermediaries toward direct manufacturer relationships. All solicitations require compliance with cGMP, FDA standards, safety data sheets, and expiration-date warranties, with wholesaler-mediated distribution and insurance requirements typical across state and local pharmaceutical procurement.